{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:02Z","timestamp":1792708862251,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473184"],"award-info":[{"award-number":["82473184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2024AZ(EGFR)MS-0048"],"award-info":[{"award-number":["Y-2024AZ(EGFR)MS-0048"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbamcr.2026.120223","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:34:43Z","timestamp":1790033683000},"page":"120223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic reprogramming underlying EGFR-TKI resistance in lung cancer"],"prefix":"10.1016","volume":"1873","author":[{"given":"Xiaolong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"17","key":"10.1016\/j.bbamcr.2026.120223_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172791","article-title":"Cell death, molecular targeted therapies, and metabolic reprogramming in EGFR-mutant lung cancer","volume":"17","author":"Joshi","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0015","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120223_bb0020","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120223_bb0025","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101266","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218069","article-title":"Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma","volume":"634","author":"Huang","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120223_bb0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/cac2.70068","article-title":"CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer","volume":"45","author":"Liang","year":"2025","journal-title":"Cancer Commun. (Lond.)"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120223_bb0050","article-title":"Metabolic remodelling: an accomplice for new therapeutic strategies to fight lung cancer","volume":"8","author":"Mendes","year":"2019","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"3191","key":"10.1016\/j.bbamcr.2026.120223_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40360-019-0301-2","article-title":"Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells","volume":"20","author":"Korga","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0065","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"24","key":"10.1016\/j.bbamcr.2026.120223_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2013.09.037","article-title":"Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells","volume":"23","author":"Tuccinardi","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120223_bb0075","doi-asserted-by":"crossref","first-page":"16875","DOI":"10.18632\/oncotarget.15171","article-title":"Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbamcr.2026.120223_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216964","article-title":"Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation","volume":"593","author":"Yu","year":"2024","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120223_bb0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41388-021-02133-5","article-title":"Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma","volume":"41","author":"Xia","year":"2022","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.bbamcr.2026.120223_bb0090","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-15-0375","article-title":"Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer","volume":"21","author":"De Rosa","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120223_bb0095","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1535-7163.MCT-12-1188","article-title":"Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation","volume":"12","author":"Kim","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120223_bb0100","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s12276-024-01221-2","article-title":"Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer","volume":"56","author":"Park","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"11\u221212","key":"10.1016\/j.bbamcr.2026.120223_bb0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10495-022-01751-y","article-title":"The histone deacetylase SIRT6 promotes glycolysis through the HIF-1\u03b1\/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer","volume":"27","author":"You","year":"2022","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-024-01928-8","article-title":"Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"19","key":"10.1016\/j.bbamcr.2026.120223_bb0115","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41388-025-03318-y","article-title":"Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1\/glycolysis\/H3K18la positive feedback loop","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030381","article-title":"Metformin enhances TKI-Afatinib cytotoxic effect, causing downregulation of glycolysis, epithelial-mesenchymal transition, and EGFR-signaling pathway activation in lung cancer cells","volume":"15","author":"Barrios-Bernal","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120223_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050941","article-title":"Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with EGFR TKI and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells","volume":"13","author":"Dyrstad S","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7824","key":"10.1016\/j.bbamcr.2026.120223_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41586-020-2475-6","article-title":"Mitochondrial ubiquinol oxidation is necessary for tumour growth","volume":"585","author":"Mart\u00ednez-Reyes","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120223_bb0135","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-14-2290","article-title":"SIRT1\/PGC1\u03b1-dependent increase in oxidative phosphorylation supports chemotherapy resistance of colon cancer","volume":"21","author":"Vellinga T","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"38","key":"10.1016\/j.bbamcr.2026.120223_bb0140","doi-asserted-by":"crossref","first-page":"61890","DOI":"10.18632\/oncotarget.11301","article-title":"Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells","volume":"7","author":"Ippolito","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbamcr.2026.120223_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101076","article-title":"Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance","volume":"25","author":"Hirpara","year":"2019","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-5-19","article-title":"Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures","volume":"5","author":"Chan","year":"2012","journal-title":"J. Ovarian Res."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120223_bb0155","article-title":"Enhanced oxidative phosphorylation driven by TACO1 mitochondrial translocation promotes stemness and cisplatin resistance in bladder cancer","volume":"12","author":"Deng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.613.65.2","article-title":"Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia","volume":"65","author":"Xu","year":"2005","journal-title":"Cancer Res."},{"issue":"34","key":"10.1016\/j.bbamcr.2026.120223_bb0165","article-title":"MYC\/TET3-regulated TMEM65 activates OXPHOS-SERPINB3 pathway to promote progression and cisplatin resistance in triple-negative breast cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"52","key":"10.1016\/j.bbamcr.2026.120223_bb0170","doi-asserted-by":"crossref","first-page":"86313","DOI":"10.18632\/oncotarget.13388","article-title":"Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma","volume":"7","author":"Martin","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120223_bb0175","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","article-title":"Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer","volume":"83","author":"Lin","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0180","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1038\/s41467-024-48433-8","article-title":"Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2018.07.025","article-title":"mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer","volume":"434","author":"Chiang","year":"2018","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jtho.2020.11.022","article-title":"Altered regulation of HIF-1\u03b1 in naive- and drug-resistant EGFR-mutant NSCLC: implications for a vascular endothelial growth factor-dependent phenotype","volume":"16","author":"Nilsson","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5930","key":"10.1016\/j.bbamcr.2026.120223_bb0195","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.05.005","article-title":"Cancer lipid metabolism confers antiangiogenic drug resistance","volume":"28","author":"Iwamoto","year":"2018","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0210","first-page":"369","article-title":"Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach","volume":"30","author":"Liu","year":"2010","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120223_bb0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbamcr.2026.120223_bb0220","article-title":"Direct visualization of de novo lipogenesis in single living cells","volume":"4","author":"Li","year":"2014","journal-title":"Sci. Rep."},{"issue":"7635","key":"10.1016\/j.bbamcr.2026.120223_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36","volume":"541","author":"Pascual","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0230","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","article-title":"Cholesteryl ester accumulation induced by PTEN loss and PI3K\/AKT activation underlies human prostate cancer aggressiveness","volume":"19","author":"Yue","year":"2014","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbrc.2011.06.101","article-title":"Cancer-associated adipocytes promotes breast tumor radioresistance","volume":"411","author":"Bochet","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120223_bb0240","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","article-title":"Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion","volume":"71","author":"Dirat","year":"2011","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.bbamcr.2026.120223_bb0245","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1111\/febs.70081","article-title":"The influence of fatty acid metabolism on T cell function in lung cancer","volume":"292","author":"Petiti","year":"2025","journal-title":"FEBS J."},{"issue":"49","key":"10.1016\/j.bbamcr.2026.120223_bb0250","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1038\/s41388-021-02057-0","article-title":"Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0255","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"34","key":"10.1016\/j.bbamcr.2026.120223_bb0260","doi-asserted-by":"crossref","first-page":"E4966","DOI":"10.1073\/pnas.1603244113","article-title":"Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120223_bb0265","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/cas.70113","article-title":"Dauricine overcomes osimertinib resistance in lung cancer by inducing ferroptosis via stabilizing SAT1","volume":"116","author":"Men","year":"2025","journal-title":"Cancer Sci."},{"issue":"Pt 1","key":"10.1016\/j.bbamcr.2026.120223_bb0270","article-title":"Gut microbiome metabolites in lung cancer: the emerging importance of short-chain fatty acids","volume":"168","author":"Bishoyi","year":"2026","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-019-1120-4","article-title":"Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer","volume":"38","author":"Huang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120223_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.12.020","article-title":"Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression","volume":"29","author":"Ericksen","year":"2019","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-19-1023","article-title":"Inactivation of the AMPK-GATA3-ECHS1 pathway induces fatty acid synthesis that promotes clear cell renal cell carcinoma growth","volume":"80","author":"Qu","year":"2020","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbrc.2017.02.101","article-title":"Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function","volume":"486","author":"Zhang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120223_bb0295","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1042\/BCJ20190754","article-title":"Leucine and branched-chain amino acid metabolism contribute to the growth of bone sarcomas by regulating AMPK and mTORC1 signaling","volume":"477","author":"Martin","year":"2020","journal-title":"Biochem. J."},{"issue":"31","key":"10.1016\/j.bbamcr.2026.120223_bb0300","doi-asserted-by":"crossref","first-page":"31522","DOI":"10.18632\/oncotarget.5159","article-title":"BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.bbamcr.2026.120223_bb0305","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-23-3748","article-title":"MYLK-AS1 enhances glutamine metabolism to promote EGFR inhibitor resistance in non-small cell lung cancer","volume":"85","author":"Qu","year":"2025","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.06.026","article-title":"Branched-chain amino acid metabolic reprogramming orchestrates drug resistance to EGFR tyrosine kinase inhibitors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0315","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jare.2024.02.023","article-title":"Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer","volume":"68","author":"Li","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120274","article-title":"Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer","volume":"291","author":"Kim","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccell.2019.12.011","article-title":"Emerging roles for branched-chain amino acid metabolism in cancer","volume":"37","author":"Sivanand","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120223_bb0330","first-page":"762","article-title":"PHGDH as a mechanism for resistance in metabolically-driven cancers","volume":"3","author":"Rathore","year":"2020","journal-title":"Cancer Drug Resist."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120223_bb0335","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.7150\/thno.23177","article-title":"Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/onc.2016.206","article-title":"Extracellular purines, purinergic receptors and tumor growth","volume":"36","author":"Di Virgilio","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13048-022-01022-z","article-title":"Targeting purine metabolism in ovarian cancer","volume":"15","author":"Liu","year":"2022","journal-title":"J. Ovarian Res."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120223_bb0350","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41416-025-03282-0","article-title":"Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role","volume":"134","author":"Ramesh","year":"2026","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120223_bb0355","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1158\/1541-7786.MCR-18-1068","article-title":"Urea cycle sustains cellular energetics upon EGFR inhibition in EGFR-mutant NSCLC","volume":"17","author":"Pham-Danis","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120223_bb0360","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41417-022-00504-y","article-title":"MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0365","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-024-03184-8","article-title":"HIF-1\u03b1-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma","volume":"43","author":"Geng","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8096","key":"10.1016\/j.bbamcr.2026.120223_bb0370","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-025-09710-8","article-title":"Targeting FSP1 triggers ferroptosis in lung cancer","volume":"649","author":"Wu","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bbamcr.2026.120223_bb0375","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jare.2025.05.033","article-title":"Heme oxygenase 1 (HO-1) is a drug target for reversing cisplatin resistance in non-small cell lung cancer","volume":"80","author":"Mei","year":"2026","journal-title":"J. Adv. Res."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120223_bb0380","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41401-020-0443-1","article-title":"NRF2-GPX4\/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells","volume":"42","author":"Ma","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120223_bb0385","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41418-024-01427-x","article-title":"Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer","volume":"32","author":"Zhao","year":"2025","journal-title":"Cell Death Differ."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120223_bb0390","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.62347\/GSBB1090","article-title":"The dual role of SLC7A11 in tumor drug resistance: mechanisms, challenges, and therapeutic potential","volume":"15","author":"Guo","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120223_bb0395","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-24-2745","article-title":"SCD1 inhibition blocks the AKT-NRF2-SLC7A11 pathway to induce lipid metabolism remodeling and Ferroptosis priming in lung adenocarcinoma","volume":"85","author":"Sen","year":"2025","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120223_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/nu17071262","article-title":"Soybean lecithin-gallic acid complex sensitizes lung cancer cells to radiation through ferroptosis regulated by Nrf2\/SLC7A11\/GPX4 pathway","volume":"17","author":"Chen","year":"2025","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120223_bb0405","doi-asserted-by":"crossref","first-page":"786","DOI":"10.21037\/tlcr-22-318","article-title":"Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bbamcr.2026.120223_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103928","article-title":"Loss of NLN suppresses lung cancer progression by inducing ferroptosis through downregulating m(6)A methylation of GPX4","volume":"88","author":"Liu","year":"2025","journal-title":"Redox Biol."},{"issue":"18","key":"10.1016\/j.bbamcr.2026.120223_bb0415","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"43","key":"10.1016\/j.bbamcr.2026.120223_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci. Immunol."},{"issue":"Pt B","key":"10.1016\/j.bbamcr.2026.120223_bb0425","article-title":"Prediction and immune infiltration analysis of lipid metabolism-related immune genes in the treatment of non-small cell lung cancer","volume":"196","author":"Jinbo","year":"2025","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0430","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"issue":"17","key":"10.1016\/j.bbamcr.2026.120223_bb0435","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177606","article-title":"Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models","volume":"134","author":"Verma","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218219","article-title":"HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8(+) T cell glutamine metabolism via KIR3DL3 interaction","volume":"639","author":"Wu","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"De La Cruz-L\u00f3pez K","year":"2019","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120223_bb0450","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1158\/0008-5472.CAN-18-3726","article-title":"The tumor metabolic microenvironment: lessons from lactate","volume":"79","author":"Garc\u00eda-Ca\u00f1averas","year":"2019","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120223_bb0455","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120223_bb0460","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In vivo CD4(+) T cell differentiation and function: revisiting the Th1\/Th2 paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu. Rev. Immunol."},{"issue":"6510","key":"10.1016\/j.bbamcr.2026.120223_bb0465","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0475","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1038\/s41467-025-60958-0","article-title":"Caffeine enhances antitumor T-cell activity by suppressing kynurenine pathway in colorectal cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120223_bb0480","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cac2.12608","article-title":"Tryptophan 2,3-dioxygenase-positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine-mediated ferroptosis resistance of metastatic cells and T cell dysfunction","volume":"44","author":"Liu","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120223_bb0485","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","article-title":"Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis","volume":"72","author":"Fong","year":"2023","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0490","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/0008-5472.CAN-24-4162","article-title":"PRMT3 drives IDO1-dependent radioresistance and immunosuppression by promoting kynurenine metabolism in non-small cell lung Cancer","volume":"86","author":"Zhang","year":"2026","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0495","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41597-024-04169-0","article-title":"Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI","volume":"11","author":"Lou","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.bbamcr.2026.120223_bb0500","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1016\/j.csbj.2025.10.010","article-title":"Plasma metabolomic analysis in Thai EGFR-mutated non-small cell lung cancer patients","volume":"27","author":"Thamlikitkul","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"22","key":"10.1016\/j.bbamcr.2026.120223_bb0505","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-25-0993","article-title":"Multiomics and single-cell insights reveal a lysophosphatidic acid-mediated resistant mechanism to third-generation EGFR-TKI in non-small cell lung cancer","volume":"31","author":"Gao","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120223_bb0510","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.21037\/tlcr-20-1153","article-title":"Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance","volume":"10","author":"Han","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120223_bb0515","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2553","article-title":"Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"Arrieta","year":"2019","journal-title":"JAMA Oncol."},{"issue":"23","key":"10.1016\/j.bbamcr.2026.120223_bb0520","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1158\/1078-0432.CCR-19-0437","article-title":"Combination of metformin and Gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase II trial","volume":"25","author":"Li","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120223_bb0525","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-10-2525","article-title":"A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer","volume":"17","author":"Han","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120223_bb0530","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4143\/crt.2016.546","article-title":"Randomized phase II study of Afatinib plus simvastatin versus Afatinib alone in previously treated patients with advanced nonadenocarcinomatous non-small cell lung cancer","volume":"49","author":"Lee","year":"2017","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120223_bb0535","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","article-title":"A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors","volume":"71","author":"Raez","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0540","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13871","article-title":"Metabolic reprogramming in cancer: implications for immunosuppressive microenvironment","volume":"174","author":"Aden","year":"2025","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120223_bb0545","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s43018-024-00811-3","article-title":"Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b\/2 clinical trial and correlative analyses","volume":"5","author":"Dinardo","year":"2024","journal-title":"Nat. Cancer"},{"issue":"14","key":"10.1016\/j.bbamcr.2026.120223_bb0550","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung Cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbamcr.2026.120223_bb0555","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-19-1789","article-title":"A tumor agnostic therapeutic strategy for hexokinase 1-null\/hexokinase 2-positive cancers","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120223_bb0560","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-017-02733-4","article-title":"Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin","volume":"9","author":"Dewaal","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120223_bb0565","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s42255-020-0195-8","article-title":"Identifying strategies to target the metabolic flexibility of tumours","volume":"2","author":"M\u00e9ndez-Lucas","year":"2020","journal-title":"Nat. Metab."},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120223_bb0570","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1158\/0008-5472.CAN-13-2893-T","article-title":"Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization","volume":"74","author":"Lim","year":"2014","journal-title":"Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:30:58Z","timestamp":1792708258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488926001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":114,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0167488926001229"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120223","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic reprogramming underlying EGFR-TKI resistance in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120223"}}